Latest Articlesddd

Prohost Letter #376

March 11, 2015 0

Prohost Letter #376 WHILE LOOKING AT THE BIOTECHS SCIENTIFIC FUNDAMENTALS We keep an eye on other …

Exelixis: On the Road Towards Accomplishments with Faster Steps

February 19, 2015 0

Exelixis Announces Acceptance of New Drug Application for Cobimetinib (NDA) in Combination with Vemurafenib for Treatment …

Aerie Pharmaceuticals Is Speeding Towards Improving the Magement of Glaucoma

February 11, 2015 0

AERIE PHARMACEUTICALS (AERI) A YOUNG BUT STRONG COMPETITOR IN THE GLAUCOMA HUGE MARKET – Aerie Pharmaceuticals …

Irrational Selloff Adding More Irrational Volatility

February 4, 2015 0

They jumped to call the biotech sector a bubble, accentuating its volatility. Instead of saying WOW …

Prohost Letter #375 Part 2

February 3, 2015 0

Prohost Letter #375 Part 2 Novel Breakthrough Cancer Immunotherapy Approaches PART 2 In Part 1 of this …

Prohost Letter #375 Part 1

January 29, 2015 0

Prohost Letter #375 Part 1 BIOTECHNOLOGY: THE BEGINNING OF A NEW ERA STATE- OF-THE-ART APPROACHES FOR THE …

Has the Time Come to Appreciate Agenus?

January 9, 2015 0

Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies Today’s news is good for …